Editas Medicine Inc logo

Editas Medicine Inc Investor Relations Material

Editas Medicine, a genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company seeks to address the fundamental flaws in existing approaches to genetic and infectious diseases by developing TALEN and CRISPR genome editing systems that function more efficiently than existing technologies. It has invented lymphocyte-directed gene therapy that uses CRISPR/Cas9 technology to manufacture a novel endonuclease. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts

Upcoming events for

Q3 20222022-11-03

Latest company events

Ticker symbol



United States of America

Investor Relations Page


Dig deeper into the Editas Medicine Inc fundamentals on Quartr.

  • Conference calls from all over the world
  • Search for anything across all transcripts
  • Consensus estimates
  • Comprehensive financial data
  • Read the transcripts or scroll the deck
  • Slide decks and earnings reports
App store link
Android play link
Quartr app screenshot